報價延遲最少15分鐘:2025/07/21 07:03 EDT
盤前時段
|
||||
|
16.54 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.11
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.79/1.18
|
|
企業價值
1.79B
|
| 資產負債 |
|
每股賬面淨值
0.37
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
233.18M
|
|
每股收益
2.61
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/21 07:03 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. |
